medigraphic.com
ISSN 1995-9494 (Electronic)
Revista del Hospital Clínico Quirúrgico "Arnaldo Milián Castro"

2016, Number 4

<< Back Next >>

Acta Med Cent 2016; 10 (4)

Caracterización analítica e histológica del hígado graso no alcohólico en pacientes diabéticos tipo II

González GEL, López MVM, Díaz OSE, Arce NM, Medina GY, Suárez GM

Language: Spanish
References: 21
Page: 36-45
PDF size: 239.52 Kb.


ABSTRACT

Nonalcoholic fatty liver is frequently associated to diabetes mellitus not insulin-dependent. In order to describe its biochemical, sonographic and histological aspects in a group of diabetic patients non-insulin dependent it was realized a cross-sectional descriptive study at “Arnaldo Milián Castro” Hospital in the period between September 2013 and January 2016. The sample was consisted of 22 patients who were underwent to determination of waist/hip index, analytical evaluation and the findings were pointed out histopathological of the liver. The relationships between some risk factors of progression of the disease and the results of liver biopsy were described. The glycemia was the most altered biochemical parameter (81.8%), followed by alanine aminotransferase and lipid profile (77.3% each one); 68.2% of patients had steatohepatitis with fibrosis; the alanine aminotransferase rose by 77.3% of patients with steatohepatitis and a significant association between the last and the increase of waist/hip index was found. Advanced stages should be suspected in nonalcoholic fatty liver in patients with diabetes non-insulin dependent.


REFERENCES

  1. Callen L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallol J, et al. Cannabinoid receptors CB1 and CB2 form functional heteromers in brain. J Biol Chem [Internet]. 2012 [citado 10 Feb 2016];77(3):287(25):20851-65. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22532560

  2. Valenzuela C, Castillo V, Ronco AM, Aguirre C, Hirsch S, Llanos M. Sistema endocanabinoide y esteatosis hepática. Rev Méd Chile [Internet]. 2014 [citado 10 Feb 2016];142(3):353-360. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872014000300010

  3. Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol [Internet]. 2011 [citado 10 Feb 2016];163(7):1432-40. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21457226

  4. Louvet A, Texeira-Clerc F, Chobert MN, Deveaux V, Pavoine C, Zimmer A, et al. Cannabinoid CB2 receptors protects against alcoholic liver disease by regulating Kupffer cell polarization in mice. Hepatology [Internet]. 2011 [citado 10 Feb 2016];54(4):1217-26. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21735467

  5. Yilmaz Y. NAFLD in the absence of metabolic syndrome: different epidemiology, pathogenetic mechanisms, risk factors for disease progression? Semin Liver Dis [Internet]. 2012 [citado 10 Feb 2016];32(1):14-21. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22418884

  6. Tailleux A, Wouters K, Staels B. Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta [Internet]. 2012 [citado 10 Feb 2016];1821(5):809-18. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22056763

  7. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia [Internet]. 2012 [citado 10 Feb 2016];55(4):885-904. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22278337

  8. Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. J Diabetes Res [Internet]. 2012 [citado 10 Feb 2016];2012 ID 716404:[aprox. 13 p.]. Disponible en: http://www.hindawi.com/journals/jdr/2012/716404/

  9. Liechti F, Dufour JF. Treatment of NASH with ursodeoxycholic acid: cons. Clin Res Hepatol Gastroenterol [Internet]. 2012 [citado 10 Feb 2016];36 Suppl 1:S46-52. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/23141894

  10. 10.Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am J Gastroenterol [Internet]. 2012 [citado 10 Feb 2016];107(7):976-8. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22764020

  11. 11.Kim MS, Kung S, Grewal T, Roufogalis BD. Methodologies for investigating natural medicines for the treatment of nonalcoholic fatty liver disease (NAFLD). Curr Pharm Biotechnol Internet]. 2011 [citado 10 Feb 2016];13(2):278-291.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21470125

  12. 12.Di Rosa M, Malaguarnera L. Genetic variants in candidate genes influencing NAFLD progression. J Mol Med (Berl) [Internet]. 2011 [citado 10 Feb 2016];90(2):105-118. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21894552

  13. 13.Caporaso N, Morisco F, Camera S, Graziani G, Donnarumma L, Ritieni A. Dietary approach in the prevention and treatment of NAFLD. Front Biosci (Landmark Ed) [Internet]. 2012 [citado 10 Feb 2016];17:2259-68. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22652776

  14. 14.Bonora E, Targher G. Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol [Internet]. 2011 [citado 10 Feb 2016];9(7):372-381. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22565095

  15. 15.Okanoue T. Recent progress in the research of NASH/ NAFLD in Japan. Nihon Shokakibyo Gakkai Zasshi [Internet]. 2011 [citado 10 Feb 2016];108(7):1161-1169. Disponible en: https://www.jstage.jst.go.jp/article/nisshoshi/108/7/108_7_1161/_pdf

  16. 16.Valenzuela CA, Castillo VA, Aguirre CA, Ronco AM, Llanos MN. The CB1 receptor antagonist SR141716A reverses adult male mice overweight and metabolic alterations induced by early stress. Obesity (Silver Spring) [Internet]. 2011 [citado 10 Feb 2016];19(1):29-35. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20559305

  17. 17.Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology [Internet]. 2012 [citado 10 Feb 2016];142(5):1218-1228. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22307032

  18. 18.Tam J, Cinar R, Liu J, Godlewski G, Wesley D, Jourdan T, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab [Internet]. 2012 [citado 10 Feb 2016];16(2):167-79. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/22841573

  19. 19.Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology [Internet]. 2010 [citado 10 Feb 2016;52(2):472-9. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/20683947

  20. 20.Mallat A, Teixeira-Clerc F, Deveaux V, Manin S, Lotersztajn S. The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openings. Br J Pharmacol [Internet]. 2011 [citado 10 Feb 2016];163(7):1432-40. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/21457226

  21. 21.McLarnon A. Liver: potential of resistance exercise as a lipid-lowering treatment for NAFLD that is independent of weight loss. Nat Rev Gastroenterol Hepatol [Internet]. 2011 [citado 10 Feb 2016];8:476. Disponible en: http://www.nature.com/nrgastro/journal/v8/n9/full/nrgastro.2011.137.html




2020     |     www.medigraphic.com